Posts found in:
Grantees

Jeffrey Bednarski MD, PhD

Jeffrey Bednarski MD, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“B Cell Specific DNA Damage Responses Prevent Leukemic Transformation” Pediatric acute lymphoblastic leukemia occurs as a result of genetic mutations that block normal development of immune cells and promote continued expansion of cancer cells. The goals of Dr. Bednarksi’s project is to understand how cells prevent generation of these mutations and how cells are eliminated […]

Read more
Daniel Herranz Benito, PhD

Daniel Herranz Benito, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“The role of SIRT1 in the pathogenesis and treatment of T-Cell Acute Lymphoblastic Leukemia” T-Cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive blood cancer where 20-50% of patients relapse, and there are few therapeutic options at this stage. Notch1 activating mutations are the main driver in T-ALL. However, responses observed with targeted therapies against NOTCH1 […]

Read more
Ann Mullally, MD

Ann Mullally, MD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Biology and Therapeutic Targeting of Mutant Calreticulin in Myeloproliferative Neoplasms” Somatic mutations in celreticulin (CALR)are frequent and disease-initiating in myeloproliferative neoplasms (MPN). Dr. Mullally’s laboratory recently elucidated the mechanism by which mutant CALR is oncogenic and induces MPN. Building on this work and guided by strong preliminary data they have generated, she will now identify […]

Read more
Richard Possemato, PhD

Richard Possemato, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Modulating Iron Metabolism to Treat Myelodysplastic Syndrome” In Myelodysplastic Syndrome red blood cell formation is impaired, leading to severe progressive anemia. Mutation of SF3B1 often causes Myelodysplastic Syndrome, and is associated with the appearance of iron-loaded immature red blood cells. We propose to use genetic tools to repair this altered iron metabolism, restoring red blood […]

Read more
Esther Obeng, MD

Esther Obeng, MD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Targeting SF3B1 in myelodysplastic syndrome” Myelodysplastic syndromes (MDS) are a group of pre-leukemia blood disorders with a high risk of progression to aggressive leukemia, SF3B1 mutations are frequent, early events in MDS pathogenesis and ideal therapeutic targets. The proposed studies will evaluate how SF3B1 mutations cause MDS and test novel agents in SF3B1-mutant cells.

Read more
Bilal Omer, MD

Bilal Omer, MD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Engineering more potent T cells to target lymphoma associated antigens” We have developed strategies to grow a patient’s own immune cells in the laboratory and then re-inject them into the patient to fight lymphoma. In a clinical trial at our center, 3 of 7 patients with active lymphoma responded to this treatment without the need […]

Read more
Elli Papaemmanuil, PhD

Elli Papaemmanuil, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

“Investigating the Impact of Oncologic Therapy on Clonal Hematopiesis and Subsequent Risk of Developing Therapy Related Leukemia” Dr. Papammanuil will study the key risk factors that lead to the therapy related leukemia development in cancer patient survivors. We will combine clinical, molecular and treatment information in a cohort of 45,000 patients to study disease biology […]

Read more
Kathrin Milbury, PhD

Kathrin Milbury, PhD

Published: Jul 10, 2019   |   Author: Keisha Escoffery   |   No Comments

Mind-body Medicine for Adolescents and Young Adults (AYA) Coping with Hodgkin Lymphoma  Dr. Milbury will conduct a pilot randomized controlled trial to test the feasibility and initial efficacy of a mind-body intervention targeting the psychosocial needs of adolescents and young adults (AYAs; ages 15-39) with Hodgkin Lymphoma.  AYAs with a new Hodgkin Lymphoma diagnosis will complete […]

Read more
Andrea Ventura, MD, PhD

Andrea Ventura, MD, PhD

Published: Jun 19, 2018   |   Author: Jen Ranieri   |   No Comments

Investigating the roles of microRNAs in lymphomagenesis A microRNA is a small RNA that can simultaneously modulate the levels of tens or even hundreds of different proteins. We propose to use multiple experimental approaches to investigate the functions of two families of miRNAs that are suspected to play a key role in lymphomas. To learn […]

Read more
Ross L. Levine, MD

Ross L. Levine, MD

Published: Jun 19, 2018   |   Author: Jen Ranieri   |   No Comments

Genomic characterizations of myeloproliferative neoplasms The Levine Lab studies chronic leukemias which manifest as an excess of red blood cells, platelets, and white blood cells, respectively. Importantly, these patients are at high risk for developing bone marrow failure (due to increased scar tissue in their bone marrow) or transformation to acute leukemia; when patients develop […]

Read more
David Frank, MD, PhD

David Frank, MD, PhD

Published: Jun 13, 2018   |   Author: Keisha Escoffery   |   No Comments

The Development of STAT Inhibitors as Novel Anti-Leukemia Agents: Use of Semi-Random Synthesis Technology In recent years, tremendous advances have been made toward understanding the molecular abnormalities occurring in tumor cells. During this time, however, relatively little progress has been made in the treatment of leukemias and other forms of cancer. The challenge, therefore, is […]

Read more
Eric C. Carnes, PhD

Eric C. Carnes, PhD

Published: Jun 13, 2018   |   Author: Keisha Escoffery   |   No Comments

Targeted Nanotherapeutics for Treatment of Acute Leukemia Dr. Carnes’ research employs materials developed using state-of-the-art nanotechnology combined with cutting-edge cell recognition systems to create microscopic suitcases which carry drugs directly to cancer cells. Control over simple properties such as the size and appearance of these tiny packages will allow us to deliver virtually any combination […]

Read more